Edgestream Partners L.P. Purchases 11,493 Shares of Illumina, Inc. (NASDAQ:ILMN)

Edgestream Partners L.P. grew its position in Illumina, Inc. (NASDAQ:ILMN) by 94.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 23,705 shares of the life sciences company’s stock after buying an additional 11,493 shares during the period. Edgestream Partners L.P.’s holdings in Illumina were worth $3,168,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. WCM Investment Management LLC increased its holdings in shares of Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after acquiring an additional 867,673 shares in the last quarter. ARK Investment Management LLC bought a new position in Illumina in the fourth quarter valued at approximately $91,714,000. Massachusetts Financial Services Co. MA boosted its holdings in shares of Illumina by 148.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock valued at $137,735,000 after buying an additional 631,294 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after acquiring an additional 625,245 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in Illumina by 116.9% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company’s stock valued at $115,663,000 after acquiring an additional 466,519 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

ILMN opened at $86.62 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The company has a market capitalization of $13.72 billion, a PE ratio of -11.28, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The business has a fifty day simple moving average of $118.38 and a 200 day simple moving average of $131.49. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of research reports. Piper Sandler boosted their price target on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Morgan Stanley cut their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 11th. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a research note on Friday, February 28th. Robert W. Baird lowered their target price on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday. Finally, Canaccord Genuity Group decreased their price target on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and a consensus price target of $149.25.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.